SHANGHAI – Canbridge Life Sciences Inc., of Beijing, is on its way to bridging the gap that leaves many patients in China waiting anywhere from four years to six years for critical treatments approved in developed markets. With time of the essence, the firm is taking a portfolio approach to its in-licensing strategy, developing both clinical-stage and approved treatments, while mixing new drugs with treatments classified as medical devices.
SHANGHAI – Merck KGaA, of Darmstadt, Germany, has reiterated its commitment to China, forging ahead with its €80 million (US$107.3 million) manufacturing plant, expected to be Merck's second largest globally and its first such pharmaceutical investment in China.
SHANGHAI – HD Biosciences Co. Ltd. has signed an agreement to co-develop drugs with two research centers at Marshall University. The deal was struck after three years of informal collaboration between both sides, and with an eye to entering the clinic in the next two years. The focus of the alliance is to provide innovative medicines for unmet medical needs, particularly cancer and kidney fibrosis, in both China and the U.S.
SHANGHAI – Pharmamar SA, of Madrid, has licensed the commercial rights to Aplidin (plitidepsin), an antitumour agent for multiple myeloma used in conjunction with dexamethasone, to Chugai Pharmaceutical Marketing Ltd., the European arm of Japanese parent company Chugai Pharmaceutical.
SHANGHAI – Cellular Biomedicine Group Inc. (CBMG) of Shanghai, has had a busy month, successfully listing on Nasdaq as the first "pureplay" biotech company from China and closing a $10 million stock transaction.
SHANGHAI – Cellular Biomedicine Group Inc. (CBMG), of Shanghai, has had a busy month, successfully listing on Nasdaq as the first "pureplay" biotech company from China and closing a $10 million stock transaction.
SHANGHAI – HD Biosciences Co. Ltd. has signed an agreement to co-develop drugs with two research centers at Marshall University. The deal was struck after three years of informal collaboration between both sides, and with an eye to entering the clinic in the next two years. The focus of the alliance is to provide innovative medicines for unmet medical needs, particularly cancer and kidney fibrosis, in both China and the U.S.
SHANGHAI – In March 2014, the Chinese government set an ambitious target of privatizing 20 percent of hospital beds by the end of 2015. For most, the target seems unrealistic and unlikely to be met in time, while a few are wading into this unknown territory and finding opportunity.
SHANGHAI – In March 2014, the Chinese government set an ambitious target of privatizing 20 percent of hospital beds by the end of 2015. For most, the target seems unrealistic and unlikely to be met in time, while a few are wading into this unknown territory and finding opportunity.
SHANGHAI – Yabao Pharmaceutical Co. Inc., of Beijing, has entered a partnership with Eli Lilly and Co. to co-develop Lilly's leading glucokinase activator (GKA), LY2608204, for China's diabetics.
